New LockeT Data Accepted in Leading Electrophysiology Journal

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced acceptance of a manuscript in the Journal of Interventional Cardiac Electrophysiology on April 6, 2026. The study of LockeT in 139 patients reported high procedural success, rapid hemostasis, early ambulation, and low complication rates for large-bore venous access closure.

The peer-reviewed acceptance supports LockeT as a feasible venous closure strategy in electrophysiology practice and may aid the company’s commercialization and hospital engagement efforts in the US and Europe.

AI-generated analysis. Not financial advice.

Positive

• Peer-reviewed validation from JICE after a 139-patient study
• Clinical outcomes reported: high procedural success and rapid hemostasis
• Supports commercialization by bolstering hospital interest in US and Europe

Negative

• None.

News Market Reaction – VTAK

+2.14%

4 alerts

+2.14% News Effect

-12.4% Trough Tracked

+$54K Valuation Impact

$2.56M Market Cap

0.0x Rel. Volume

On the day this news was published, VTAK gained 2.14%, reflecting a moderate positive market reaction. Argus tracked a trough of -12.4% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $54K to the company's valuation, bringing the market cap to $2.56M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patient count: 139 patients

1 metrics

Patient count 139 patients LockeT large-bore venous access closure study published in JICE

Market Reality Check

Price: $0.8897 Vol: Volume 346,726 is far bel...

low vol

$0.8897 Last Close

Volume Volume 346,726 is far below 20-day average of 3,209,738 (relative volume 0.11). low

Technical Shares at $0.93 are trading below the $2.55 200-day moving average and only modestly above the 52-week low of $0.85, versus a 52-week high of $15.68.

Peers on Argus

Sector peers show mixed moves, with some up (e.g., BBLG +5.08%, BJDX +3.51%) and...

1 Down

Sector peers show mixed moves, with some up (e.g., BBLG +5.08%, BJDX +3.51%) and others down (e.g., VERO -24.31%, NAOV -1.95%). Momentum scanner only flags TIVC down 2.98%, suggesting this VTAK news is stock-specific rather than a broad sector move.

Historical Context

5 past events · Latest: Apr 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 02	Strategic advisor engagement	Positive	-1.1%	Hired advisor to market cardiac electrophysiology business for potential sale.
Mar 31	Earnings and strategy	Negative	-3.8%	Reported 2025 results with revenue growth but significant net loss and expansion plans.
Mar 25	Flyte platform expansion	Positive	-4.2%	Detailed growth of Flyte Vision Jet Hops regional aviation platform and fleet plans.
Mar 16	Flyte Florida launch	Positive	+4.4%	Launched Flyte Hops Florida with strong initial bookings and fleet expansion goals.
Mar 11	Financing commitments	Positive	-7.0%	Announced up to $88M in institutional financing and completed Flyte acquisition.

Pattern Detected

Recent ostensibly positive strategic, growth, and financing announcements have often coincided with negative next-day price reactions, with only one noted event showing a positive move.

Recent Company History

Over the last month, VTAK has shifted from a pure cardiac electrophysiology story toward a dual-platform model with aviation, then moved to formally market its electrophysiology business for sale. Key events since Mar 11, 2026 include up to $88M in institutional financing commitments, the Flyte acquisition and Hops route expansion, 2025 financial results with strong percentage revenue growth but ongoing losses, and the April 2 engagement of a strategic advisor to monetize VIVO and LockeT. Today’s LockeT data publication fits the effort to enhance the value of these medical assets.

Market Pulse Summary

This announcement adds peer‑reviewed validation for LockeT in a 139‑patient series, supporting its s...

Analysis

This announcement adds peer‑reviewed validation for LockeT in a 139‑patient series, supporting its safety and efficacy for large‑bore venous access closure in electrophysiology procedures. It strengthens the clinical narrative around an asset the company recently began formally marketing for sale, alongside its VIVO system, while pivoting toward aviation via Flyte. Investors monitoring this story may focus on how such publications influence the perceived value of the electrophysiology portfolio against a backdrop of financing needs and strategic transactions disclosed in recent SEC filings.

Key Terms

suture retention device, large-bore venous access closure, electrophysiology, hemostasis, +2 more

6 terms

suture retention device medical

"Safety and Efficacy of LockeT Suture Retention Device for Large-Bore Venous Access"

A suture retention device is a small medical tool used during wound closure to hold stitches in place and spread the force of the stitch over a larger area of skin or tissue, similar to how a button or washer prevents a rope from cutting through fabric. For investors, these devices matter because they can reduce wound complications, shorten surgery or recovery time, and lower follow-up costs—factors that affect hospital adoption, reimbursement, and market demand.

large-bore venous access closure medical

"LockeT Suture Retention Device for Large-Bore Venous Access Closure"

A large-bore venous access closure is a medical technique or device used to seal the access point in a large vein after removal of a wide catheter or sheath used during procedures. Think of it like plugging and patching a hole left by a large straw to stop bleeding and speed healing; for investors, effective closures matter because they reduce complications, shorten hospital stays, lower follow-up costs, and influence adoption and reimbursement of related medical devices and services.

electrophysiology medical

"a leading medical journal in the field of electrophysiology"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

hemostasis medical

"LockeT demonstrated high procedural success, rapid hemostasis, early ambulation"

Hemostasis is the body’s process for stopping bleeding, using a coordinated set of responses that form clots and seal damaged vessels—think of it as the body's natural emergency patch and repair crew. It matters to investors because drugs, medical devices, and diagnostics that influence hemostasis can affect patient outcomes, regulatory approval paths, and market demand for treatments of bleeding disorders or clot-related conditions, so advances or safety issues can materially impact company value.

ambulation medical

"LockeT demonstrated high procedural success, rapid hemostasis, early ambulation"

Ambulation is the ability of a patient to move around under their own power, typically by walking or using a mobility aid. Investors watch ambulation as a simple, real-world measure of how well a treatment, device, or care program restores independence and reduces hospital stays or long-term care needs—think of it as a basic fitness test that affects patient outcomes, costs, and reimbursement incentives.

venous closure medical

"low complication rates for venous closure following EP procedures"

Venous closure is a medical procedure or device used to seal or block a vein, either to stop bleeding after catheter-based interventions or to treat problematic veins such as varicose veins. It matters to investors because the safety, effectiveness, regulatory approval, and reimbursement of venous closure products influence hospital adoption, procedure volumes, and the market value of companies that make or sell these devices—think of it as a key tool that can expand or limit a firm’s revenue from vascular care.

AI-generated analysis. Not financial advice.

FORT MILL, S.C., April 06, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that the manuscript titled “Safety and Efficacy of LockeT Suture Retention Device for Large-Bore Venous Access Closure” has been accepted by the Journal of Interventional Cardiac Electrophysiology (JICE), a leading medical journal in the field of electrophysiology.

This publication confirmed the safety and efficacy of LockeT for large-bore venous closure in 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring LBVA. These findings support LockeT as a feasible and effective venous closure strategy in contemporary EP practice.

David Jenkins, CEO of Catheter Precision, says, “This peer-reviewed validation from JICE reinforces our position that LockeT is a beneficial product for the physicians, patients and hospitals. The acceptance of study data in a prestigious medical journal underscores the importance of the data and enables Catheter Precision to continue its mission of product innovation.”

Mr. Jenkins continued, “This additional publication on LockeT technology coupled with expanded hospital interest in both the US and Europe converges into our strategy of unlocking value in this product line.”

Last week VTAK announced the engagement of a strategic advisor to assist in the company of exploring various options for its distinctive electrophysiology products.

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

What did Catheter Precision (VTAK) announce about LockeT on April 6, 2026?

They announced manuscript acceptance in JICE reporting LockeT safety and efficacy in 139 patients. According to the company, the study found high procedural success, rapid hemostasis, early ambulation and low complication rates for large-bore venous access closure.

How many patients were included in the LockeT study accepted by JICE for VTAK?

The accepted manuscript reported data from 139 patients. According to the company, these results demonstrated procedural success, rapid hemostasis, early ambulation and low complication rates after EP procedures requiring LBVA.

What clinical outcomes did the LockeT JICE paper report for VTAK's device?

The paper reported high procedural success, rapid hemostasis, early ambulation and low complication rates. According to the company, these findings support LockeT as a feasible venous closure strategy in contemporary EP practice.

Does the JICE publication affect Catheter Precision’s (VTAK) commercialization strategy?

The company says the peer-reviewed publication supports commercialization by reinforcing clinical credibility. According to the company, the acceptance may aid expanded hospital interest in both the US and Europe for LockeT adoption.

What recent advisory engagement did Catheter Precision (VTAK) announce alongside the JICE acceptance?

VTAK said it engaged a strategic advisor to explore options for its electrophysiology products. According to the company, the advisor will assist in evaluating strategic alternatives for the LockeT product line and broader EP portfolio.